Our client was considering an expansion on indications within its target therapeutic group via licensing and acquiring products that were in clinical development or already marketed.
The client engaged Pacific Tiger Consulting to prepare a commercial valuation of a late-stage licensing opportunity to support assessment of a go/no-go decision
Pacific Tiger Consulting began the engagement by developing a detailed understanding of the disease area, addressable patient population and competitive landscape of all marketed and pipeline drugs. Pacific Tiger Consulting analyzed the scientific data and commercial capabilities of the target assets in comparison to available and pipeline treatment options.
Findings were triangulated based on interviews with payers and KOLs to inform potential clinical use and pricing power. Insights gained on the market, clinical, regulatory and commercial parameters were used to assess the target asset value, based on risk-adjusted net present value (NPV) analysis. Sensitivity of forecasts was assessed through key inputs such as market share and pricing.
Based on Pacific Tiger Consulting’s analysis and recommendations, the client was able to understand the market opportunity for the drug in development and make a go/no-go decision and submit a non-binding offer to the target company.
New York, NY
contact@pacifictigerconsulting.com
© Pacific Tiger Consulting 2021. All Rights Reserved.